S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.51 (-2.76%)
AAPL   141.82 (-0.94%)
MSFT   232.06 (-0.12%)
FB   271.77 (-3.64%)
GOOGL   1,801.47 (-5.58%)
AMZN   3,240.23 (-2.58%)
TSLA   868.25 (-1.68%)
NVDA   515.24 (-4.13%)
BABA   261.51 (-1.66%)
CGC   37.75 (+6.28%)
GE   10.87 (-3.72%)
MU   74.94 (-5.75%)
AMD   88.96 (-6.07%)
NIO   56.97 (-5.54%)
T   29.22 (-1.78%)
F   10.80 (-3.49%)
ACB   11.34 (+6.28%)
BA   193.75 (-4.11%)
DIS   162.98 (-3.88%)
NFLX   531.75 (-5.37%)
GILD   65.55 (-1.72%)
S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.51 (-2.76%)
AAPL   141.82 (-0.94%)
MSFT   232.06 (-0.12%)
FB   271.77 (-3.64%)
GOOGL   1,801.47 (-5.58%)
AMZN   3,240.23 (-2.58%)
TSLA   868.25 (-1.68%)
NVDA   515.24 (-4.13%)
BABA   261.51 (-1.66%)
CGC   37.75 (+6.28%)
GE   10.87 (-3.72%)
MU   74.94 (-5.75%)
AMD   88.96 (-6.07%)
NIO   56.97 (-5.54%)
T   29.22 (-1.78%)
F   10.80 (-3.49%)
ACB   11.34 (+6.28%)
BA   193.75 (-4.11%)
DIS   162.98 (-3.88%)
NFLX   531.75 (-5.37%)
GILD   65.55 (-1.72%)
S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.51 (-2.76%)
AAPL   141.82 (-0.94%)
MSFT   232.06 (-0.12%)
FB   271.77 (-3.64%)
GOOGL   1,801.47 (-5.58%)
AMZN   3,240.23 (-2.58%)
TSLA   868.25 (-1.68%)
NVDA   515.24 (-4.13%)
BABA   261.51 (-1.66%)
CGC   37.75 (+6.28%)
GE   10.87 (-3.72%)
MU   74.94 (-5.75%)
AMD   88.96 (-6.07%)
NIO   56.97 (-5.54%)
T   29.22 (-1.78%)
F   10.80 (-3.49%)
ACB   11.34 (+6.28%)
BA   193.75 (-4.11%)
DIS   162.98 (-3.88%)
NFLX   531.75 (-5.37%)
GILD   65.55 (-1.72%)
S&P 500   3,739.54 (-2.86%)
DOW   30,276.42 (-2.14%)
QQQ   319.51 (-2.76%)
AAPL   141.82 (-0.94%)
MSFT   232.06 (-0.12%)
FB   271.77 (-3.64%)
GOOGL   1,801.47 (-5.58%)
AMZN   3,240.23 (-2.58%)
TSLA   868.25 (-1.68%)
NVDA   515.24 (-4.13%)
BABA   261.51 (-1.66%)
CGC   37.75 (+6.28%)
GE   10.87 (-3.72%)
MU   74.94 (-5.75%)
AMD   88.96 (-6.07%)
NIO   56.97 (-5.54%)
T   29.22 (-1.78%)
F   10.80 (-3.49%)
ACB   11.34 (+6.28%)
BA   193.75 (-4.11%)
DIS   162.98 (-3.88%)
NFLX   531.75 (-5.37%)
GILD   65.55 (-1.72%)
Log in

Best Stocks Under $10.00 for 2021

A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks under 10 dollars, there are some important things to know.

SHOULD I BUY STOCKS UNDER $10?

The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable.

The problem with this approach is it assumes “high price good, low price bad.” And in fairness, that can be true. And you should not read another word of this article without internalizing this simple truth. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth.

So the first thing I would say to investors looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish.

But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals.

And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you.

But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend.

You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market.

HOW IS A COMPANY’S SHARE PRICE CALCULATED?

If you’re a more experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions.

To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for.

The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought.

To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares.

Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10.

The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company.

Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59.

66.37/8.74 = 7.59

This means at that moment, one share of GE stock was valued at $7.59.

WHY DO COMPANIES ISSUE SHARES?

Remember earlier when looked at the example of two companies that were both valued at $100 million. Why would one company have 100 million shares available and the other only 1 million?

First of all, if you’re asking that question good for you. You’re on your way to being a sound investor. But understanding the answer is equally important. So let’s go back to the basics so you understand why companies issue shares.

Companies issue shares as a way to raise money that they don’t have to pay back. This is because, unlike a loan where a company borrows money from a financial institution or hedge fund, shares are bought and sold by other investors. That’s why it’s an investment, right? An investor is giving the company money (in the form of share purchases) in return for the chance that the share price will go higher. This means the value of the company will rise.

So in the earlier example, the company that only has 1 million shares outstanding has a higher demand for its stock. Therefore, if all things are equal (i.e. the market cap of the two companies are the same), that company’s stock will be more valuable.

WHAT ARE THE REWARDS OF STOCKS UNDER $10?

The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were

That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment.

That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could only buy about five shares of Amazon (NASDAQ:AMZN). But they could buy over 150 shares of Lovesac (NASDAQ:LOVE), a furniture retailer that is currently trading below $7 a share.

This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks.

WHAT ARE THE RISKS OF STOCKS UNDER $10?

One of the risks of buying a stock that is priced under $10 is the risk of share dilution. Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers. In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.

However, when a company gets into financial trouble, it becomes difficult for them to get loans. Think of your personal finances. If you are looking to finance a car or a house, banks want to make sure you have enough available cash on a monthly basis so you can make the payment.

It’s no different for a company. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.

When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further.

Issuing new shares is different from a stock split. A company that offers a stock split is simply trying to make its stock less expensive for retail (individual) investors. But when a company issues a split, they are giving current shareholders more shares at a lower price (e.g. an investor that owned 100 shares at $40 now owns 200 shares at $20).

Another risk with buying stocks under $10 includes the risk of increased competition. Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels.

Yet another risk to buying stocks under $10 is that they may be in a cyclical industry. A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink.

A final risk to consider is the stock is what it is, a low- to no-growth stock. If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend.

WHAT ARE THE BEST STOCKS UNDER $10?

If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-off’s in history.

On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price.

Stocks Under 10 Dollars

Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value.

One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider.


Bird Construction logo

#1 - Bird Construction

OTCMKTS:BIRDF
Stock Price: $6.78 (-$0.04)
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.40 (53.5% Upside)
Bird Construction Inc. operates as a general contractor in Canada. The company primarily focuses on projects in the industrial, commercial, and institutional sectors of the general contracting industry. It constructs industrial buildings; and performs civil construction operations, including site preparation, concrete foundations, metal and modular fabrication, mechanical process work, underground piping, and earthwork for clients primarily operating in the oil and gas, liquefied natural gas, mining, and nuclear sectors. The company also engages in the construction and renovation of shopping malls, big box stores, office buildings, hotels, and selected high rise condominiums and apartments; and the construction of hospitals, post-secondary education facilities, schools, prisons, courthouses, government buildings, and retirement and senior housing facilities, as well as environmental facilities, such as water and wastewater treatment centers, composting facilities, and biosolids treatment and management facilities. It serves clients in the commercial, institutional, retail, multi-tenant residential, industrial, mining, water and wastewater, energy, civil, light industrial, and renovation and restoration sectors. Bird Construction Inc. was founded in 1920 and is based in Mississauga, Canada.
Teranga Gold logo

#2 - Teranga Gold

OTCMKTS:TGCDF
Stock Price: $9.59 (-$0.11)
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $17.75 (85.1% Upside)
Teranga Gold Corporation engages in the exploration, development, production, and sale of gold in West Africa. The company's flagship project is the Sabodala gold mine covering an area of 291 square kilometers mine license and 629 square kilometers exploration land package located in the Republic of Senegal. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Viking Therapeutics logo

#3 - Viking Therapeutics

NASDAQ:VKTX
Stock Price: $7.67 (+$0.07)
PE Ratio: -15.65
Market Cap: $554.44 million
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.44 (114.4% Upside)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
CymaBay Therapeutics logo

#4 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $5.55 (-$0.23)
PE Ratio: -5.90
Market Cap: $398.17 million
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.77 (130.1% Upside)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Oaktree Specialty Lending logo

#5 - Oaktree Specialty Lending

NASDAQ:OCSL
Stock Price: $5.64 (-$0.13)
PE Ratio: 20.14
Market Cap: $813.35 million
P/E Ratio: 20.1
Dividend Yield: 7.65 %
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.20 (-7.8% Upside)
Oaktree Specialty Lending Corporation is a business development company specializing in investments in middle market, bridge financing, first and second lien debt financing, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, and management buyouts in small and mid-sized companies. The fund seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering, and media and advertising sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies with enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies.
Anavex Life Sciences logo

#6 - Anavex Life Sciences

NASDAQ:AVXL
Stock Price: $6.11 (+$0.02)
PE Ratio: -13.58
Market Cap: $407.81 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.60 (106.2% Upside)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Carrols Restaurant Group logo

#7 - Carrols Restaurant Group

NASDAQ:TAST
Stock Price: $6.38 (-$0.13)
PE Ratio: -14.18
Market Cap: $339.12 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.58 (18.9% Upside)
Carrols Restaurant Group, Inc., through its subsidiaries, operates as a restaurant company in the United States. The company operates as a Burger King franchisee. As of December 29, 2019, it had, as franchisee, 1,036 Burger King restaurants located in 23 Northeastern, Midwestern, and Southeastern states; and 65 Popeyes restaurants in seven Southeastern states. The company was founded in 1960 and is headquartered in Syracuse, New York.
Ardelyx logo

#8 - Ardelyx

NASDAQ:ARDX
Stock Price: $6.96 (-$0.40)
PE Ratio: -6.89
Market Cap: $664.23 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.00 (86.8% Upside)
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
SCYNEXIS logo

#9 - SCYNEXIS

NASDAQ:SCYX
Stock Price: $7.01 (-$0.36)
PE Ratio: -1.88
Market Cap: $80.63 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $30.29 (332.0% Upside)
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Progenity logo

#10 - Progenity

NASDAQ:PROG
Stock Price: $7.25 (-$0.02)
Market Cap: $397.10 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.00 (51.7% Upside)
Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.
LexinFintech logo

#11 - LexinFintech

NASDAQ:LX
Stock Price: $7.46 (-$0.24)
PE Ratio: 18.65
Market Cap: $1.35 billion
P/E Ratio: 18.7
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.20 (76.9% Upside)
LexinFintech Holdings Ltd., through its subsidiaries, operates as an online consumer finance platform for young professionals in the People's Republic of China. The company operates Fenqile.com, a retail and online consumer finance platform that offers installment purchase loans, personal installment loans, and other loan products, as well as provides online direct sales with installment payment terms; and Le Card, a membership platform, which offers savings, benefits, and membership privileges to food and beverage, apparel, hospitality, and leisure sectors. It also matches customer loans with diversified funding sources, including individual investors on its Juzi Licai online investment platform, third-party commercial banks, consumer finance companies, institutional funding partners in its direct lending programs, investors of its asset-backed securities, and other licensed financial institutions. The company was formerly known as Staging Finance Holding Ltd. and changed its name to LexinFintech Holdings Ltd. in March 2017. LexinFintech Holdings Ltd. was founded in 2013 and is headquartered in Shenzhen, the People's Republic of China.
Catalyst Pharmaceuticals logo

#12 - Catalyst Pharmaceuticals

NASDAQ:CPRX
Stock Price: $3.60 (-$0.10)
PE Ratio: 5.37
Market Cap: $383.50 million
P/E Ratio: 5.4
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.88 (146.5% Upside)
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Mogo logo

#13 - Mogo

NASDAQ:MOGO
Stock Price: $3.93 (-$0.10)
PE Ratio: -8.54
Market Cap: $121.10 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.30 (9.4% Upside)
Mogo Inc. operates as a financial technology company in Canada. The company provides finance app that empowers consumers with solutions to help them get in control of their financial wellness. It offers users a free MogoAccount and provides access to various products, including free credit score monitoring, identity fraud protection, digital spending account with Platinum Prepaid Visa Card, digital mortgage experience, the MogoCrypto account, a product within MogoWealth that enables the buying and selling of bitcoin, and access to smart consumer credit products through. The company's platform delivers digital experience with various products all through one account. Mogo Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
LiveXLive Media logo

#14 - LiveXLive Media

NASDAQ:LIVX
Stock Price: $4.00 (-$0.32)
PE Ratio: -6.90
Market Cap: $311.49 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.35 (33.8% Upside)
LiveXLive Media, Inc., a digital media company, engages in the acquisition, distribution, and monetization of live music, Internet radio, podcasting, and music-related streaming and video content. It operates LiveXLive, a live music streaming platform; and Slacker Radio, a streaming music service, as well as produces original music-related content. The company also produces, edits, curates, and streams live music events through broadband transmission over the Internet and satellite networks to its users; provides digital Internet radio and music services to users online and through original equipment manufacturers on a white label basis; and offers ancillary products and services, such as regulatory and post-implementation support services. In addition, it offers an application that provides access to live events, audio streams, original episodic content, podcasts, video on demand, real-time livestreams, and social sharing of content. The company was formerly known as Loton, Corp. and changed its name to LiveXLive Media, Inc. in August 2017. LiveXLive Media, Inc. was founded in 2009 and is headquartered in West Hollywood, California.
Aptose Biosciences logo

#15 - Aptose Biosciences

NASDAQ:APTO
Stock Price: $4.25
PE Ratio: -6.64
Market Cap: $377.57 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.29 (165.5% Upside)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Sientra logo

#16 - Sientra

NASDAQ:SIEN
Stock Price: $4.43 (-$0.43)
PE Ratio: -2.49
Market Cap: $245.21 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.20 (62.5% Upside)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Applied Genetic Technologies logo

#17 - Applied Genetic Technologies

NASDAQ:AGTC
Stock Price: $4.48 (-$0.24)
PE Ratio: -2.10
Market Cap: $122.09 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.10 (259.4% Upside)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Kadmon logo

#18 - Kadmon

NASDAQ:KDMN
Stock Price: $4.90 (-$0.37)
PE Ratio: -8.17
Market Cap: $903.87 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (185.7% Upside)
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Aquestive Therapeutics logo

#19 - Aquestive Therapeutics

NASDAQ:AQST
Stock Price: $5.38 (-$0.15)
PE Ratio: -3.52
Market Cap: $185.92 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $15.67 (191.2% Upside)
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Fortress Biotech logo

#20 - Fortress Biotech

NASDAQ:FBIO
Stock Price: $3.19 (-$0.15)
PE Ratio: -3.75
Market Cap: $312.97 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.55 (136.7% Upside)
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.